Abstract Submission Topics

Topics for abstract submission are as below*:

I. Aging and Sarcopenia
a. Metabolic pathways and signaling
b. Genomic and other means of high risk identification
c. Validation of targets
d. Animal model studies
e. Evaluation of candidate interventions (nutritional, pharmacologic, life style) 
f. Methods to interpret translatability of animal results
g. Clinical efficacy endpoints validation (functional and person-reported instruments) 
h. Proposed clinical design approaches
i. New clinical study results
j. Epidemiology analysis and studies 
k. Comparison of major regulatory positions
l. Specific bioethical considerations

II. Cancer
a. Metabolic pathways and signaling
b. Validated targets
c. Animal study results
d. Utility of animal models
e. Evaluation of current and novel candidate interventions (nutritional, pharmacologic, life style)
f. Genomic and other means of high risk identification
g. Clinical studies
h. Epidemiology analysis and studies 
i. Meta-analyses of clinical studies and lessons learned from chemoprevention trials

III.  Diabetes
a. Metabolic pathway and signaling
b. Islet biology (embryogenesis and homeostasis of islet mass and function)
c. Immunity (pathogenesis and interventions)
d. Validation of metabolic, inflammatory, and immunologic targets
e. Animal model studies
f. Methods to enhance translation of animal results
g. Genomic and other means of high risk identification
h. Clinical efficacy endpoints validation 
i. Proposed clinical design approaches
j. Clinical studies
k. New analyses of reported clinical trials 
l. Lessons learned from T1D and T2D prevention trials
m. Comparison of major regulatory positions

IV. Neurodegeneration
a. Metabolic pathway and signaling
b. Validation of targets
c. Animal model studies
d. Methods to enhance translation of animal results
e. Clinical efficacy endpoints validation 
f. Proposed clinical design approaches
g. Clinical studies
h. Comparison of major regulatory positions

V.      Metabesity—general approaches and tools
a. Metabesity pathways and signaling (choke points and pleotropic agents that leverage 2 or more major clinical outcomes)
b. Animal model development
c. Biomarkers and imaging
d. Efficacy endpoints—functional, quality life survival, person-reported
e. Microbiome (mechanisms, characterization, interventions)
f. General issues related to repurposing approved therapies
g. Acquiring and managing big data
h. Biostatistical methods
i. Cost-effectiveness approaches relevant to payors and policy makers
j. Regulatory approaches
k. “Apps” and other engagement and tracking tools
l. Education 
m. Econometrics
n. Bioethics 
o. Public policy and public health approaches

*The organizers will consider adding new categories for submitted abstracts that do not fall into the above categories